Skip to main content
logo
Forte Biosciences, Inc. (FBRX)
Aug 27, 2026 - FBRX was delisted (reason: acquired by ARGX)
76.99
0.00 (0.00%)
Inactive · Last trade price on Aug 26, 2026

[Name] Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Selling, General & Admin
15.0512.4115.4110.628.37.63
Research & Development
79.7458.2521.1921.865.5913.85
Operating Expenses
94.870.6636.632.4913.921.49
Operating Income
-94.8-70.66-36.6-32.49-13.9-21.49
Interest & Investment Income
2.722.721.311.120.16-
Other Non Operating Income (Expenses)
0.14-0.4-0.19-0.11-0.15-0.22
EBT Excluding Unusual Items
-91.94-68.34-35.48-31.48-13.88-21.71
Pretax Income
-86.33-68.34-35.48-31.48-13.88-21.71
Income Tax Expense
1.61.04----
Net Income
-87.94-69.38-35.48-31.48-13.88-21.71
Net Income to Common
-87.94-69.38-35.48-31.48-13.88-21.71
Net Income Growth
------
Shares Outstanding (Basic)
19153111
Shares Outstanding (Diluted)
19153111
Shares Change
148.66%404.74%130.90%81.61%24.45%89.81%
EPS (Basic)
-4.55-4.71-12.17-24.92-19.96-38.85
EPS (Diluted)
-4.55-4.71-12.17-24.92-19.96-38.85
EPS Growth
------

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
-72.03-51-30.78-28.79-8.19-16.68
Free Cash Flow Per Share
-3.72-3.46-10.56-22.80-11.77-29.85
EBITDA
-94.72-70.59-36.56-32.48-13.86-21.45
D&A For EBITDA
0.080.060.040.010.040.04
EBIT
-94.8-70.66-36.6-32.49-13.9-21.49
SEC Filings: 10-K · 10-Q